State-of-the-Art Review : Chemotherapy and Thrombosis in Gynecologic Malignancy

Abstract

References

Heilmann L. , von Tempelhoff G-F. , Schneider DM Prevention of thrombosis in gynecological malignancy. Clin Appl Thromb Hemost 1998;4:153.

Clahsen PC , Cornelis JH , van der Velde JPJ , et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cooperative Group Study. J Clin Oncol 1994;12:1266.

von Tempelhoff G-F. , Wolf H. , Herrle B. , et al. Low molecular weight heparin. Clin Appl Thromb Hemost 1996;2:292.

Heilmann L. , von Tempelhoff G-F. , Herrle B. , et al. Low-Dose Heparin versus niedermolekulares Heparin zur Thromboseprophylaxe in der operativen gynäkologischen Onkologie. Geburtsh und Frauenheilk 1997;57:1.

Saphner T. , Tormey DC , Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286.

Levine MN , Gent M. , Hirsh J. , et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404.

Pemberton KD , Melissari E. , Kakkar VV The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis 1993;4:935.

Goldhaber SZ Epidemiology of pulmonary embolie and deep vein thrombosis. In: Bloom AL , Forbes ChD , Thomas DP , Tuddenham EGD , eds. Haemostasis and Thrombosis. New York: Churchill Livingston, 1994:1327.

Ludwig H. Klinisch—experimentelle Untersuchungen zur thromobotischen Diathese bei der gynäkologischen Radiumbehandlung. Geburtsh Frauenhlk 1962;22:1121.

10.

Graf AH , Graf B. , Riedl B. , et al. Risiko und Prophylaxe thromboembolischer Komplikationen beim Zervix—und Korpuskarzinom. Gynäkol Geburtshilf Rundsch 1994;34(suppl 1):95.

11.

Graf AH , Graf B. , Traun H. , et al. Risiko und Prophylaxe thromboembolischer Komplikationen bei gynäkologischen Malignomen. Gynäkol Geburtshilf Rundsch 1996;36:37

12.

Saeger W. , Genzkow M. Venous thromboses and pulmonary embolisms in post-mortem series: probable causes by correlation of clinical data and basic diseases. Pathol Res Pract 1994; 190:394.

13.

Berek JS , Hacker NF Practical gynecologic oncology. Baltimore, Philadelphia, Hong Kong: Williams & Wilkins, 1994:377.

14.

Fowkes Fgr , Pell JP , Donnan PT , et al. Sex differences in susceptibility to etiologic factors for peripheral atherosclerosis. Arterioscler Thromb 1994; 14:862.

15.

Semeraro N. , Montemurro P. , Conese M. , et al. Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynecologic malignancies . Int J Cancer 1990;45: 251.

16.

Mellor H. , Taylor I. , Roath S. , Francis JL Whole blood procoagulant activity in breast and colorectal cancer. J Clin Pathol 1989; 42:489.

17.

Moradi MM , Carson LF , Weinberg B. , et al. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor alpha in patients with ovarian epithelial cancer . Cancer 1993;72:2433.

18.

Edwards RL , Silver J. , Rickles FR Human tumor procoagulants. Registry of the subcommittee on haemostasis and malignancy of the scientific and standardization committee, international society on thrombosis and haemostasis. Thromb Haemost 1993;69:205.

19.

Zacharski LR , Memoli VA , Ornstein DL , et al. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 1993;85:1225.

20.

Contrino J. , Hair G. , Kreutzer DL , Rickles FR In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2: 209.

21.

Zhang Y. , Deng Y. , Luther T. , et al. Tissue Factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320.

22.

Constantino V. , Zacharski LR , Memoli VA , et al. Occurrence of compounds of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue. Cancer Res 1991;1:354.

23.

Pujade-Lauraine E. , Lu H. , Mirshahi S. , et al. The plasminogen-activation system in ovarian tumors. Int J Cancer 1993;55:27.

24.

Schmalfeldt B. , Kuhn W. , Reuning U. , et al. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptors and inhibitors type 1 and 2. Cancer Res 1995;55:3958.

25.

Casslén B. , Bossmar T. , Lecander I. , Astedt B. Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J Cancer 1994;30A: 1209.

26.

von Tempelhoff G-F , Heilmann L. , Dietrich M. , et al. Plasmatic plasminogen activator inhibitor activity in patients with primary breast cancer. Thromb Haemost 1997;77:606.

27.

Uchiyama T. , Matsumoto M. , Kobayashi N. Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy. Thromb Res 1990;59:955.

28.

Nielsen HJ , Pappot H. , Christensen IJ , et al. Association between plasma PAI-1 levels and survival in patients with colorectal cancer. BMJ 1997:316:829.

29.

de Jong E. , Knot Ear , Iburg Ahc , et al. Increased plasminogen activator inhibitor activator inhibition levels in malignancy. Thromb Haemost 1987;57:140.

30.

Newland JR , Haire WD Elevated plasminogen activator inhibitor levels found in patients with malignant conditions. Am J Clin Pathol 1991;96:602.

31.

Mahadevan V. , Hart IR Metastasis and angiogenesis. Rev Oncol 1990;3:97.

32.

Mueller-Berghaus G. Physiologie des Hämostasesystems. In: Müller-Berghaus C , ed. Transfusionsmedizin Berlin, Heidelberg, New York: Springer, 1996:45.

33.

Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996;75:536.

34.

Bick RL , Baker WF Antiphospholipid and thrombosis syndromes. Semin Thromb Hemost 1994;20:3.

35.

Zuckerman E. , Toubi E. , Golan TD , et al. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer 1995;72:447.

36.

Falanga A. , Ofosu FA , Cortelazzo F. , et al. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993;85:745.

37.

Iversen LH , Okholm M. , Thorlacius-Ussing O. Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease—a preliminary study. Thromb Haemost 1996;76:523.

38.

Gadducci A. , Baicchi U. , Marrai R. , et al. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses . Gynecol Oncol 1996;60:197.

39.

von Tempelhoff G-F. , Niemann F. , Schneider D. , et al. Gerinnungsuntersuchungen und Thromboseinzidenz während der Cisplatin/ Epirubicin/Cyclophosphamid Chemotherapy beim Ovarialkarzinom . Geburtsh Frauenhlk 1997;57:595.

40.

von Tempelhoff G-F , Dietrich M. , Niemann F. , et al. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997;77:456.

41.

von Tempelhoff G-F. Changes of hemorrheology and clotting in different gynecologic malignancies. Clin Hemorheol 1995;15: 261.

42.

von Tempelhoff G-F. , Heilmann L. , Hommel G. , et al. Hyperviscosity syndrome in ovarian malignancy. Cancer 1998;82:1104.

43.

Rampling MW , Whittingstall MW , Linderkamp O. The effects of fibrinogen and its plasmin degradation products on the rheology of erythrocyte suspension. Clin Hemorheol 1984;4:533.

44.

Lowe Gdo. Blood rheology and venous thrombosis. Clin Hemorheol 1984;4:571.

45.

Thomas DP Pathogenesis of venous thrombosis. In: Colman RW , Hirsh J , Marder VJ , Salzman EW , eds. Hemostasis and Thrombosis. Philadelphia: J.B. Lippincott, 1982:820.

46.

Mercke CE Anemia in patients with solid tumors and the role of erythrocyte deformability . Br J Cancer 1981;44:425.

47.

Balendra R. , Rumley A. , Orr M. , et al. Blood lipids, coagulation, fibrinolysis and rheology in spontaneous proven deep vein thrombosis [Abstract]. Br J Haematol 1991;79(suppl 1):83.

48.

von Tempelhoff G-F. , Heilmann L. , Berg C. , et al. Comparison of pretreatment clotting estimations in 428 patients with gynecologic malignancy [Abstract]. Thromb Haemost 1997;77(suppl): 123.

49.

McCulloch P. , Nieuwenhuizen W. , Douglas J. , et al. Coagulation disturbance in cancer of the breast and colon measured with specific monoclonal antibody enzyme immunoassay for fibrin-fibrinogen degradation products. Haemostasis 1990;20:73.

50.

Neises M. , Schäfer T. , Strittmann H-J. , et al. D-dimer und Plasminogen Aktivator vom Urokinasetyp: Eigene Erfahrungen bei Mammakarzinomen. Geburtsh Frauenhlk 1993 ;53:455.

51.

von Tempelhoff G-F , Dietrich M. , Hommel G. , Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophos-phamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol 1996; 14:2560.

52.

Mitter CG , Zielinski CC Plasma levels of D-dimer: a crosslinked fibrin-degradation product in female breast cancer. J Cancer Res Clin Oncol 1990 ;117:259.

53.

Prins MH , Turpie Agg. Diagnosis and treatment of venous thromboembolism. In: Bloom AL , Forbes ChD , Thomas DP , Tuddenham EGD , eds. Haemostasis and Thrombosis. New York: Churchill Livingstone, 1994:1381.

54.

Weiss RB , Tormey DC , Holland F. , Weinberg VE Venous thrombosis during multimodal treatment of primary breast carcinoma . Cancer Treat Res 1981;65:677.

55.

Bonadonna G. , Gianni L. , Santoro A. , et al. Drugs ten years later: epirubicin . Ann Oncol 1993;4:359.

56.

Rifkin SE , Green S. , Metch B. Adjuvant CMFVP versus tamoxifen concurrent CMFVP and tamoxifen for postmenopausal node positive estrogen receptor positive breast cancer patients: a South-west Oncology Group Study. J Clin Oncol 1994;12:2078.

57.

Bonadonna G. , Valagussa P. The contribution of medicine to the primary treatment of breast cancer. Cancer Res 1988 ;48:2314.

58.

Levine M. , Hirsh J. , Gent M. , et al. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886.

59.

Falanga A. , Levine MN , Consonni R. , et al. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial. Thromb Haemost 1998;79:23.

60.

Goodnough LT , Saito H. , Manni A. , et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with five drug chemotherapy regimen . Cancer 1984;54:1264.

61.

Manni A. , Trujillo JE , Pearson OH Therapy and chemotherapy for metastatic breast cancer: effects on survival . Cancer Treat Res 1980;64:111.

62.

Wall JG , Weiss RB , Norton L. Arterial thrombosis associated with adjuvant chemotherapy for breast cancer: a cancer and leukemia group B study. Am J Med 1989;87:501.

63.

Pritchard KI , Paterson Ahg , Paul NA , et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 1996;14:2731.

64.

Fisher B. , Redmond C. , Legault-Poisson D. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive node breast cancer patients aged 50 years and older with tumours responsive to tamoxifen: results from the national surgical adjuvant breast and bowel project B16. J Clin Oncol 1990;8:1005.

65.

Bober-Sorcinelli K. , Farber LV , Lundberg WB , et al. Thromboembolic disease in breast cancer patients receiving chemo/ hormonal therapy [Abstract]. Proc Asco 1986;5:64.

66.

Canney PA , Wilkinson PM Pulmonary embolism in patients receiving chemotherapy for advanced ovarian cancer. Eur J Cancer Clin Oncol 1985;21:585.

67.

Fisher B. , Constatino J. , Redmond C. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor positive tumours . N Engl J Med 1989;320:479.

68.

Love RR , Surawicz TS , Williams EC Anti thrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med 1992;152:317.

69.

Mamby CC , Love RR , Feyzi JM Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women. Breast Cancer Res Treat 1994;30:311.

70.

McDonald CC Alexancer FE , Whyte BW , et al. for the Scottish cancer trials breast group. Cardiac and vascular morbidity in women receiving tamoxifen for breast cancer in a randomised trial. BMJ 1995;311:977.

71.

Hayes DF , van Zyl JA , Hacking A. , et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995; 13:2556.

72.

Beex L. , Pieters G. , Smals A. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Res 1981;65:179.

73.

Lipton A. , Harvey HA , Hamilton RW Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Res 1984;68: 887.

74.

Castiglione-Gertsch M. , Pampallona S. , Varini M. , et al. Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate . Ann Oncol 1994;4:735.

75.

Gershanovich M. , Garin A. , Baltina D. , et al. Eastern European Study Group. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with adjuvant breast cancer. Breast Cancer Res Treat 1997;46:251.

76.

Pannuti F. , Martoni A. , Cilent G. , et al. Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in pre-menopausal patients. Eur J Cancer Clin Oncol 1988;24:423.

77.

Bastert G. , Michel RT Hochdosierte Gestagentherapie mit Medroxyprogesteronacetat (HD-MPA) beim metastasierenden Mammkarzinom. Med Welt 1984;34:61.

78.

Pollow K. , Kreienberg R. , Juchem M. , Hoffmann G. Hochdosierte Medroxyprogesteronacetat (MPA)—Therapie beim fortgeschrittenen Mammakarzinom unter besondere Berücksichtigung der MPA Serumspiegel. Tumordiagn u Ther 1993;14:49.

79.

Della Cuna GR , Calciati A. , Strada Mrb , et al. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation . Tumori 1978;64: 143.

80.

Samonis G. , Margioris AN , Bafaloukos D. , Razis DV Prospective randomized study of aminogluthethimide (AG) versus medroxyprogesterone acetate (MPA) versus AG + MPA in generalized breast cancer. Oncology 1994 ;51:411.

81.

Japan Advanced Breast Cancer Study Group and Japan Clinical Oncology Group. Effects of chemoendocrine therapy on the coagulation—fibrinolytic systems in patients with advanced breast cancer. Jpn J Cancer Res 1993;84:455.

82.

Abrams JS , Gutheil J. , Aisner J. Potential applications of high-dose megestrol acetate in breast cancer. Oncology 1992;49(suppl 2):12.

83.

Buzdar A. , Jonat W. , Howell A. , et al. Anastrozole, a potent and selective aromataseinhibitor, vs. Megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase II trials. J Clin Oncol 1996;14:2000.

84.

Parnes HL , Abrams JS , Techekmedyain S. , et al. A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat 1991;18:171.

85.

Tchekmedyian S. , Tait N. , Abrams J. , Aisner J. High-dose Megestrol acetate in the treatment of advanced breast cancer. Semin Oncol 1988 ;15(suppl 1):44.

86.

Bertomeu MC , Gallo S. , Lauri D. , et al. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis 1990; 8:511.

87.

Edwards RL , Klaus M. , Mathews E. , et al. Heparin abolishes the chemotherapy induced increase in plasma fibrinopeptid A levels. Am J Med 1990;89:25.

88.

Rogers JS , Murgo AJ , Fontana JA , Raich PC Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988;6:276.

89.

Feffer SE , Carmasino LS , Fox RL Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate and 5 floururacil. Cancer 1989 ;63:1303.

90.

Rella C. , Coviello M. Giotta F. , et al. A prethrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 1996;40:151.

91.

Canobbio L. , Tassio T. , Ardizzoni R. , et al. Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients. Cancer 1986;58:1032.

92.

von Tempelhoff G-F. , Heilmann L. Thrombosis and hemorheology in patients with breast cancer and adjuvant chemotherapy. Clin Hemorheology 1995;15:311.

93.

Wieding JU , Ohl C. , Fargel M. , et al. Antithrombin III bei Patienten mit malignen Erkrankungen. In: Köstering H , eds. Antithrombin III Grundlagen, Diagnostik, klinische Bedeutung und Therapie. Stuttgard, New York: Schattauer Verlag, 1984:87.

94.

Rutqvist E. , Mattson A. for the Stockholm Breast Cancer Study Group. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993;85:1298.

95.

von Tempelhoff G-F , Niemann F. , Schneider D. , et al. Blood rheology during chemotherapy in patients with ovarian cancer. Thromb Res 1998;90:73.

96.

Auger MJ , Mackie MJ Effects of tamoxifen on blood coagulation. Cancer 1988;61:1316.

97.

Lox CD , Ronaghan CA , Cobos E. , Messer RH Tamoxifen-induced changes in the plasma fibrinolytic factors in menopausal women with breast cancer. Clin Appl Thromb Hemost 1997;3: 234.

98.

Pujol H. , Girault J. , Rouanet P. , et al. Phase I study of percutaneous 4 hydroxy tamoxifen with analyses of 4 hydroxy tamoxifen concentrations in breast cancer and normal tissue. Cancer Chemother Pharmacol 1995;36:493.

99.

Powles TJ , Hardy JR , Ashley SE , et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989;60:126.

100.

Yamamoto H. , Noguchi S. , Miyauchi K. , et al. Changes in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer. Jpn J Cancer Res 1991;82:420.

101.

Bonstgnori M. , Rossi G. , Sturba F. , et al. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. Chemioterapia 1986;V:134.

102.

Subramaniam S. , Subramaniam S. , Jagadeesan M. , Devi Css. Alterations in erythrocyte membrane structure of breast cancer patients treated with CMF—A lipid profile. Chemotherapy 1994; 40:427.

103.

Vasigara-Singh W. , Subramaniam S. , Shyama S. , et al. Changes in erythrocyte membrane lipids in breast cancer patients after radiotherapy and chemotherapy. Chemotherapy 1996;42:65.

104.

Chahwala SB , Hickmann JA Effects of the antitumor drug adriamycin on human blood cell discocyte-echinocyte transitions. Cancer Res 1985;45:4986.

105.

Mirshahi SS , Pupde-Lauraine E. , Sossia C. , et al. D-dimer and Ca 125 levels in patients with ovarian cancer during antineoplastic therapy. Cancer 1992;69:2289.

106.

Monreal M. , Alastue A. , Rull M. , et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices—prophylaxis with a low molecular weight heparin (Fragmin) Thromb Haemost 1996;75:251.

107.

Kakkar AK , Hedges AR , Williamson Rcn , Kakkar VV Perioperative heparin therapy inhibits late death from metastatic cancer. Int J Oncol 1995;6:885.

108.

Lebeau B. , Chastang C. , Brechot J-M. , Capron F. , et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 1994;74:38.

109.

Zacharski LR , Henderson WG , Rickles FR , et al. Effect of sodium warfarin on survival in small carcinoma of the lung. JAMA 1981;245:831.

110.

Zacharski LR , Costantini V. Blood coagulation activation in cancer: challenges for cancer treatment. Haemostaseology 1995 ;15: 14.